Reports Q3 revenue $1.195M, consensus $260,000. "The positive VRDN-001 clinical data reported today reinforces our conviction in the potential for VRDN-001 to deliver improved care for patients suffering with TED. Across all efficacy measures, VRDN-001 continues to deliver a rapid, compelling, and clinically meaningful improvement for patients after just two infusions," said Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics. "We have continued our rapid momentum with the recent initiation of our Phase 3 THRIVE program as we accelerate our portfolio of IV and SC TED assets towards approval."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
- Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
